L3VLUP
ProSign in

BMRN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BMRNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BMRN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterBMRNJNJ
Q3 202012 holders, $3.0bn30 holders, $26.2bn
Q4 202012 holders, $3.7bn32 holders, $26.6bn
Q1 202110 holders, $3.1bn31 holders, $25.3bn
Q2 202111 holders, $3.4bn37 holders, $25.6bn
Q3 202114 holders, $3.0bn40 holders, $24.1bn
Q4 202114 holders, $3.4bn33 holders, $25.2bn
Q1 202219 holders, $3.0bn35 holders, $28.2bn
Q2 202221 holders, $2.9bn33 holders, $26.9bn
Q3 202225 holders, $3.1bn36 holders, $25.4bn
Q4 202226 holders, $4.0bn35 holders, $27.6bn
Q1 202320 holders, $3.3bn42 holders, $24.5bn
Q2 202318 holders, $2.9bn38 holders, $25.0bn
Q3 202318 holders, $2.9bn37 holders, $18.9bn
Q4 202322 holders, $4.1bn31 holders, $19.0bn
Q1 202419 holders, $3.6bn32 holders, $19.7bn
Q2 202416 holders, $3.3bn35 holders, $20.4bn
Q3 202416 holders, $3.0bn28 holders, $22.3bn
Q4 202414 holders, $3.0bn37 holders, $20.4bn
Q1 202516 holders, $3.3bn32 holders, $20.5bn
Q2 202516 holders, $2.5bn31 holders, $18.4bn
Q3 202516 holders, $2.3bn32 holders, $23.7bn
Q4 202521 holders, $2.4bn29 holders, $27.8bn
Q1 202615 holders, $2.6bn34 holders, $35.6bn
Q2 202612 holders, $2.2bn33 holders, $39.1bn
BMRN

Biomarin Pharmaceutical Inc

Holders
21
Reported value
$2.4bn
Buyers
24
Sellers
19

Breadth +5 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BMRN (10)

Caxton Associates LLP, ExodusPoint Capital Management LP, Moore Capital Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Steadfast Capital Management LP, Viking Global Investors LP, Voloridge Investment Management LLC, Walleye Capital LLC, Winton Group Ltd

Only JNJ (18)

AllianceBernstein LP, Brevan Howard Capital Management LP, Capital World Investors, D. E. Shaw & Co., Element Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Invesco Ltd, Janus Henderson Group Ltd, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Rokos Capital Management LLP, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →